 Sarah Billups
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 17 | 2023 | 238 | 3.540 |
Why?
| | Bone Density Conservation Agents | 4 | 2022 | 61 | 1.830 |
Why?
| | Osteoporosis | 3 | 2023 | 229 | 1.820 |
Why?
| | Osteoporosis, Postmenopausal | 3 | 2022 | 38 | 1.360 |
Why?
| | Pharmaceutical Services | 7 | 2020 | 79 | 1.120 |
Why?
| | Hypertension | 7 | 2023 | 1203 | 1.060 |
Why?
| | Osteoporotic Fractures | 2 | 2023 | 51 | 0.980 |
Why?
| | Pharmacy Service, Hospital | 11 | 2017 | 86 | 0.890 |
Why?
| | Primary Health Care | 9 | 2023 | 1560 | 0.850 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 136 | 0.840 |
Why?
| | Communicable Diseases | 1 | 2023 | 132 | 0.810 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 174 | 0.780 |
Why?
| | Blood Pressure Determination | 2 | 2018 | 133 | 0.720 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 1864 | 0.710 |
Why?
| | Patient Transfer | 1 | 2020 | 143 | 0.650 |
Why?
| | Diphosphonates | 2 | 2015 | 50 | 0.630 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2016 | 21 | 0.600 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 664 | 0.590 |
Why?
| | Medication Adherence | 4 | 2015 | 556 | 0.590 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 66 | 0.590 |
Why?
| | Retrospective Studies | 19 | 2023 | 12978 | 0.570 |
Why?
| | Pharmacy Residencies | 1 | 2016 | 11 | 0.570 |
Why?
| | Community Pharmacy Services | 2 | 2013 | 46 | 0.560 |
Why?
| | Research | 2 | 2016 | 411 | 0.540 |
Why?
| | Telephone | 1 | 2015 | 152 | 0.490 |
Why?
| | Hospitals, Veterans | 9 | 2001 | 246 | 0.470 |
Why?
| | Pharmacies | 1 | 2014 | 31 | 0.470 |
Why?
| | Aged | 30 | 2023 | 19657 | 0.460 |
Why?
| | Patient Satisfaction | 5 | 2013 | 610 | 0.460 |
Why?
| | Patient Compliance | 5 | 2009 | 537 | 0.460 |
Why?
| | Correspondence as Topic | 2 | 2015 | 16 | 0.450 |
Why?
| | Health Maintenance Organizations | 4 | 2014 | 96 | 0.430 |
Why?
| | Professional Role | 5 | 2020 | 153 | 0.420 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2018 | 233 | 0.410 |
Why?
| | Prescription Drugs | 1 | 2013 | 113 | 0.410 |
Why?
| | Insurance, Health | 1 | 2014 | 244 | 0.410 |
Why?
| | Humans | 51 | 2023 | 118972 | 0.390 |
Why?
| | Cost Savings | 2 | 2015 | 77 | 0.390 |
Why?
| | Neuromuscular Agents | 1 | 2011 | 31 | 0.380 |
Why?
| | Drug Prescriptions | 4 | 2020 | 248 | 0.360 |
Why?
| | Drug Therapy | 2 | 2000 | 76 | 0.360 |
Why?
| | Drug Monitoring | 6 | 2014 | 187 | 0.350 |
Why?
| | Nortriptyline | 1 | 2009 | 4 | 0.350 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2009 | 2 | 0.350 |
Why?
| | Female | 38 | 2023 | 61564 | 0.350 |
Why?
| | Amitriptyline | 1 | 2009 | 21 | 0.340 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 29 | 0.340 |
Why?
| | HIV Infections | 1 | 2023 | 2459 | 0.340 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 37 | 0.340 |
Why?
| | Perception | 2 | 2023 | 314 | 0.330 |
Why?
| | Middle Aged | 23 | 2023 | 27617 | 0.330 |
Why?
| | Tetrahydronaphthalenes | 2 | 1998 | 32 | 0.320 |
Why?
| | Calcium Channel Blockers | 2 | 1998 | 117 | 0.310 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1185 | 0.310 |
Why?
| | Antihypertensive Agents | 4 | 2023 | 437 | 0.310 |
Why?
| | Aged, 80 and over | 8 | 2020 | 6561 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1200 | 0.300 |
Why?
| | Benzimidazoles | 2 | 1998 | 140 | 0.300 |
Why?
| | Pilot Projects | 2 | 2023 | 1419 | 0.290 |
Why?
| | Fractures, Bone | 1 | 2012 | 380 | 0.290 |
Why?
| | Cohort Studies | 8 | 2023 | 5116 | 0.290 |
Why?
| | Managed Care Programs | 2 | 2013 | 135 | 0.270 |
Why?
| | American Heart Association | 2 | 2020 | 270 | 0.270 |
Why?
| | Lovastatin | 1 | 2005 | 27 | 0.270 |
Why?
| | Male | 34 | 2020 | 57801 | 0.270 |
Why?
| | Colorado | 8 | 2017 | 4196 | 0.260 |
Why?
| | Simvastatin | 1 | 2005 | 65 | 0.260 |
Why?
| | Patient Acceptance of Health Care | 2 | 2023 | 687 | 0.260 |
Why?
| | Adult | 15 | 2023 | 31512 | 0.260 |
Why?
| | Ambulatory Care | 6 | 2010 | 482 | 0.260 |
Why?
| | Heart Diseases | 1 | 2008 | 341 | 0.250 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 245 | 0.250 |
Why?
| | Migraine Disorders | 2 | 2020 | 79 | 0.240 |
Why?
| | Health Care Costs | 2 | 2014 | 394 | 0.240 |
Why?
| | Bone Density | 2 | 2022 | 449 | 0.240 |
Why?
| | Cholesterol | 2 | 2020 | 373 | 0.240 |
Why?
| | Wounds and Injuries | 1 | 2011 | 772 | 0.230 |
Why?
| | Denosumab | 1 | 2022 | 7 | 0.210 |
Why?
| | Blood Pressure | 2 | 2023 | 1664 | 0.210 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1440 | 0.200 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 794 | 0.200 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 387 | 0.200 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 3 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2013 | 942 | 0.190 |
Why?
| | Young Adult | 5 | 2023 | 10793 | 0.170 |
Why?
| | Student Health Services | 1 | 2018 | 16 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2023 | 545 | 0.160 |
Why?
| | Antimanic Agents | 1 | 2018 | 15 | 0.160 |
Why?
| | Lithium Compounds | 1 | 2018 | 10 | 0.160 |
Why?
| | Angina Pectoris | 1 | 1998 | 63 | 0.160 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1998 | 64 | 0.160 |
Why?
| | Electronic Health Records | 3 | 2022 | 829 | 0.160 |
Why?
| | Drug Approval | 1 | 1998 | 77 | 0.160 |
Why?
| | Preceptorship | 1 | 2018 | 63 | 0.160 |
Why?
| | Antidepressive Agents | 2 | 2017 | 189 | 0.160 |
Why?
| | Quality of Life | 4 | 2001 | 2366 | 0.150 |
Why?
| | Guideline Adherence | 3 | 2020 | 523 | 0.150 |
Why?
| | Students, Pharmacy | 1 | 2018 | 99 | 0.150 |
Why?
| | Data Collection | 4 | 2014 | 658 | 0.150 |
Why?
| | Drug Interactions | 4 | 2012 | 352 | 0.150 |
Why?
| | Administration, Oral | 2 | 2015 | 756 | 0.140 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 193 | 0.130 |
Why?
| | Pharmaceutical Preparations | 2 | 2016 | 167 | 0.130 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 271 | 0.130 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 17 | 0.130 |
Why?
| | United States Department of Veterans Affairs | 5 | 2001 | 555 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 554 | 0.130 |
Why?
| | Patient Readmission | 1 | 2020 | 634 | 0.130 |
Why?
| | Hematinics | 1 | 2014 | 17 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2013 | 4596 | 0.120 |
Why?
| | Renal Insufficiency | 2 | 2015 | 150 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1510 | 0.120 |
Why?
| | Patient Discharge | 1 | 2020 | 796 | 0.120 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.120 |
Why?
| | United States | 13 | 2020 | 12555 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 178 | 0.120 |
Why?
| | Lipids | 1 | 2017 | 607 | 0.120 |
Why?
| | Outpatients | 1 | 2016 | 325 | 0.110 |
Why?
| | Reminder Systems | 1 | 2015 | 163 | 0.110 |
Why?
| | Anemia | 1 | 2014 | 146 | 0.110 |
Why?
| | Colchicine | 1 | 2012 | 27 | 0.110 |
Why?
| | Adolescent | 4 | 2023 | 18480 | 0.110 |
Why?
| | Hospitalization | 2 | 2018 | 1785 | 0.110 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 66 | 0.110 |
Why?
| | Gout Suppressants | 1 | 2012 | 33 | 0.110 |
Why?
| | Hematologic Diseases | 1 | 2012 | 60 | 0.110 |
Why?
| | Health Expenditures | 1 | 2014 | 174 | 0.110 |
Why?
| | Gout | 1 | 2012 | 57 | 0.100 |
Why?
| | Job Satisfaction | 1 | 2013 | 175 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 234 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 965 | 0.100 |
Why?
| | Hyperlipidemias | 3 | 2017 | 128 | 0.100 |
Why?
| | Depression | 2 | 2017 | 1132 | 0.100 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 136 | 0.100 |
Why?
| | Evaluation Studies as Topic | 1 | 2011 | 182 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2174 | 0.100 |
Why?
| | Chronic Disease | 4 | 2008 | 1636 | 0.100 |
Why?
| | Anticoagulants | 1 | 2015 | 559 | 0.100 |
Why?
| | Diazepam | 1 | 2010 | 23 | 0.090 |
Why?
| | Amiodarone | 1 | 2010 | 24 | 0.090 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 38 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2018 | 3171 | 0.090 |
Why?
| | Ipratropium | 1 | 2009 | 5 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 939 | 0.090 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 113 | 0.090 |
Why?
| | Paroxetine | 1 | 2009 | 7 | 0.090 |
Why?
| | Telemedicine | 1 | 2017 | 664 | 0.090 |
Why?
| | Heart Failure | 1 | 2022 | 1969 | 0.090 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2009 | 25 | 0.090 |
Why?
| | Bupropion | 1 | 2009 | 38 | 0.090 |
Why?
| | Time Factors | 4 | 2013 | 6412 | 0.080 |
Why?
| | Fluoxetine | 1 | 2009 | 47 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1353 | 0.080 |
Why?
| | Mibefradil | 2 | 1998 | 6 | 0.080 |
Why?
| | Risk Factors | 8 | 2018 | 9000 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2014 | 4552 | 0.080 |
Why?
| | Internet | 1 | 2013 | 633 | 0.080 |
Why?
| | Fees, Pharmaceutical | 1 | 2008 | 13 | 0.080 |
Why?
| | Blood Glucose | 1 | 2017 | 1939 | 0.080 |
Why?
| | Prospective Studies | 5 | 2015 | 6471 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2018 | 4708 | 0.080 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 253 | 0.080 |
Why?
| | Tryptamines | 1 | 2006 | 4 | 0.070 |
Why?
| | Sumatriptan | 1 | 2006 | 6 | 0.070 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 28 | 0.070 |
Why?
| | Financing, Personal | 1 | 2005 | 27 | 0.070 |
Why?
| | Drugs, Generic | 1 | 2005 | 18 | 0.070 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 86 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 134 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1052 | 0.060 |
Why?
| | Drug Costs | 1 | 2005 | 94 | 0.060 |
Why?
| | Incidence | 1 | 2011 | 2424 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1945 | 0.060 |
Why?
| | Patients | 1 | 2005 | 175 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 316 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 130 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2995 | 0.060 |
Why?
| | Medical Records Systems, Computerized | 2 | 2006 | 92 | 0.060 |
Why?
| | Sex Factors | 1 | 2009 | 1781 | 0.060 |
Why?
| | Medicaid | 2 | 2017 | 411 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 12 | 0.050 |
Why?
| | Patient Care Team | 2 | 2013 | 521 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 200 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2006 | 9342 | 0.050 |
Why?
| | Economics, Pharmaceutical | 1 | 2000 | 10 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1137 | 0.050 |
Why?
| | Medication Systems, Hospital | 1 | 1999 | 8 | 0.040 |
Why?
| | Veterans | 2 | 2001 | 1208 | 0.040 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 218 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 26 | 0.040 |
Why?
| | Community Health Centers | 1 | 2018 | 57 | 0.040 |
Why?
| | Software | 2 | 1999 | 613 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1998 | 79 | 0.040 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 589 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2018 | 147 | 0.040 |
Why?
| | Counseling | 1 | 2000 | 353 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 953 | 0.040 |
Why?
| | Prescription Drug Misuse | 1 | 2017 | 38 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 21 | 0.040 |
Why?
| | Contraindications | 1 | 2016 | 86 | 0.040 |
Why?
| | Health Status | 1 | 2001 | 726 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2015 | 45 | 0.030 |
Why?
| | Logistic Models | 1 | 2000 | 1901 | 0.030 |
Why?
| | Epoetin Alfa | 1 | 2014 | 6 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2513 | 0.030 |
Why?
| | Warfarin | 1 | 2015 | 139 | 0.030 |
Why?
| | Pain Management | 1 | 2017 | 294 | 0.030 |
Why?
| | Erythropoietin | 1 | 2014 | 82 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 1998 | 969 | 0.030 |
Why?
| | Publishing | 1 | 2015 | 131 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 17 | 0.030 |
Why?
| | Drug Overdose | 1 | 2017 | 294 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 940 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 60 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 975 | 0.030 |
Why?
| | Specialization | 1 | 2013 | 120 | 0.030 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 88 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 525 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2013 | 130 | 0.020 |
Why?
| | Hemorrhage | 1 | 2015 | 623 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1308 | 0.020 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2010 | 3 | 0.020 |
Why?
| | Thyrotropin | 1 | 2010 | 105 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 417 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2010 | 152 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2009 | 82 | 0.020 |
Why?
| | Data Interpretation, Statistical | 2 | 2001 | 336 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 263 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 827 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1798 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 34 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1527 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 520 | 0.020 |
Why?
| | Cardiology | 1 | 2010 | 272 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 169 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 556 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 159 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2326 | 0.020 |
Why?
| | Prognosis | 1 | 2013 | 3443 | 0.020 |
Why?
| | Child, Preschool | 1 | 2017 | 9491 | 0.010 |
Why?
| | Pain | 1 | 2008 | 735 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 1999 | 2874 | 0.010 |
Why?
| | Total Quality Management | 1 | 2001 | 61 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2001 | 154 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 253 | 0.010 |
Why?
| | Quality-Adjusted Life Years | 1 | 2000 | 103 | 0.010 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 138 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2000 | 86 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2001 | 218 | 0.010 |
Why?
| | Medical Records | 1 | 1999 | 163 | 0.010 |
Why?
| | Linear Models | 1 | 2001 | 827 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2001 | 295 | 0.010 |
Why?
| | Child | 1 | 2017 | 19129 | 0.010 |
Why?
| | Health Services Research | 1 | 2001 | 385 | 0.010 |
Why?
| | Attitude to Health | 1 | 2001 | 410 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2001 | 1244 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2000 | 699 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1795 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2674 | 0.010 |
Why?
|
|
Billups's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|